肿瘤坏死相关凋亡诱导配体对前列腺癌及膀胱癌细胞增殖、凋亡的作用-东南大学学报医学版

肿瘤坏死相关凋亡诱导配体对前列腺癌及膀胱癌细胞增殖、凋亡的作用

单位：1. 徐州医学院, 江苏徐州 221009;
2. 徐州市中心医院, 江苏徐州 221009

分类号：R694

出版年·卷·期（页码）：2015·34·第三期（383-386）

摘要：

目的:研究重组并纯化的肿瘤坏死因子凋亡诱导配体(TRAIL)蛋白对前列腺癌及膀胱癌细胞增殖及凋亡的影响.方法:将不同浓度的TRAIL蛋白与培养的前列腺癌细胞(PC-3细胞)和膀胱癌细胞(5637细胞)共孵育24 h后,采用细胞增殖实验及流式细胞术检测肿瘤细胞的增殖及凋亡.结果:PC-3细胞株中,与未处理组比较,TRAIL蛋白浓度在20、40、80、160 ng·ml^-1时细胞增殖率均有显著性差异;而在5637细胞株中,与未处理组比较,TRAIL蛋白浓度在5、10、20、40 ng·ml^-1时细胞增殖率均有显著性差异.流式细胞实验结果也证实,随 TRAIL蛋白浓度的增高,两种肿瘤细胞凋亡率增加.结论:重组并纯化TRAIL蛋白可通过抑制前列腺癌及膀胱癌细胞的增殖,诱导其凋亡而产生抗肿瘤的作用.

Objective: To study the effect of purified tumor necrosis factor-related apoptosis ligand on the proliferation and apoptosis of prostate cancer cell(PC-3 cell) and bladder cancer cell(5637 cell). Methods: PC-3 and 5637 cell line were incubated with different concentrations of TRAIL protein for 24 h. Then cell proliferation and flow cytometry were employed to detect the PC-3 and 5637 proliferation and apoptosis.Results: The significant difference of the cell proliferation rate was found in PC-3 cells when the TRAIL protein concentration was 20,40, 80, 160 ng·ml^-1 compared with untreated group. In 5637 cells, the cell proliferation rate had significant difference when the TRAIL protein concentration was 5, 10, 20, 40 ng·ml^-1 compared with untreated group. Flow cytometry results also confirmed that the apoptosis rate of two kinds of tumor cell increased with the TRAIL protein dose dependently. Conclusion: Purified tumor necrosis factor-related apoptosis ligand protein can perform the anti-tumor role by inhibiting proliferation and inducing the apoptosis of the prostate cancer and bladder cancer cells.

参考文献：

[1] SIEGEL R,NAISHADHAM D,JEMAL A.Cancer statistics,2012[J].CA Cancer J Clin,2012,62(1):10-29.
[2] BABJUK M,BURGER M,ZIGEUNER R,et al.EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder:Update 2013[J].Eur Urol,2013,64(4):639-653.
[3] 刘志,陶自坚.膀胱浸润性尿路上皮癌伴腺性分化(附两例报告并文献复习)[J].现代医学,2011,39(5):536-539.
[4] HERBST R S,ECKHARDT S G,KURZROCK R,et al.Phase I dose-escalation study of recombinant human Apo2L/TRAIL,a dual proapoptotic receptor agonist,in patients with advanced cancer[J].J Clin Oncol,2010,28(17):2839-2846.
[5] GALLIGAN L,LONGLEY D B,MCEWAN M,et al.Chemotherapy and TRAIL-mediated colon cancer cell death:the roles of p53,TRAIL receptors,and c-FLIP[J].Mol Cancer Ther,2005,4(12):2026-2036.
[6] 刘转转,郝林,范涛,等.人TRAIL基因原核表达载体的构建及鉴定[J].现代生物医学进展,2011,11(7):1220-1223.
[7] 郝林,刘转转,贺厚光,等.人肿瘤坏死因子相关凋亡诱导配体胞外区基因原核系统的表达与纯化[J].中华实验外科杂志,2011,28(7):1047.
[8] ISMAIL B,GHEZALI L,GUEYW R,et al.Novel methylsulfonyl chalcones as potential antiproliferative drugs for human prostate cancer:involvement of the intrinsic pathway of apoptosis[J].Int J Oncol,2013,43(4):1160-1168.
[9] KAUNTZ H,BOUSSEROUEL S,GOSSE F,et al.The flavonolignan silibinin potentiates TRAIL-induced apoptosis in human colon adenocarcinoma and in derived TRAIL-resistant metastatic cells[J].Apoptosis,2012,17(8):797-809.
[10] SHIN E A,SOHN E J,WON G,et al.Upregulation of microRNA135a-3p and death receptor 5 plays a critical role in Tanshinone Ⅰ sensitized prostate cancer cells to TRAIL induced apoptosis[J].Oncotarget,2014,5(14):5624-5636.
[11] ISMAIL B,FAGNERE C,LIMAMI Y,et al.2'-hydroxy-4-methylsulfonylchalcone enhances TRAIL-induced apoptosis in prostate cancer cells[J].Anticancer Drugs,2015,26(1):74-84.
[12] ZHANG T,QU S,SHI Q,et al.Evodiamine induces apoptosis and enhances TRAIL-induced apoptosis in human bladder cancer cells through mTOR/S6K1-mediated downregulation of Mcl-1[J].Int J Mol Sci,2014,15(2):3154-3171.
[13] ZHANG T,WANG X,HE D,et al.Metformin sensitizes human bladder cancer cells to TRAIL-induced apoptosis through mTOR/S6K1-mediated downregulation of c-FLIP[J].Anticancer Drugs,2014,25(8):887-897.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录